Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 17, 2017, eight new employees were awarded "inducement" grants of options under Rule 5635(c)(4) of the NASDAQ Marketplace Rules.

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

Pasadena. CA | Posted on October 23rd, 2017

The option grants entitle the employees, in aggregate, to purchase up to 26,000 shares of common stock outside of the Company's stockholder-approved equity incentive plans at an exercise price per share of $3.92, the last reported closing price of the Company's common stock on the date of grant. The options vest and become exercisable over a period of four years from the date of grant.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/alerts.cfm .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400

or
Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Switching with molecules: Molecular switch will facilitate the development of pioneering electro-optical devices May 25th, 2018

Tunable diamond string may hold key to quantum memory: A process similar to guitar tuning improves storage time of quantum memory May 24th, 2018

Remote control of transport through nanopores: New study outlines key factors affecting the transfer of molecules through biological channels May 24th, 2018

2018 Kavli Prizes in Astrophysics, Nanoscience, and Neuroscience to be Announced Live on May 31: Live announcement at the Norwegian Academy of Science and Letters to be streamed live at World Science Festival Event May 24th, 2018

Investments/IPO's/Splits

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) March 20th, 2018

Nanometrics to Present at the 30th Annual ROTH Conference February 27th, 2018

180 Degree Capital Corp. Reports Net Asset Value per Share of $2.60 as of December 31, 2017; A Decrease of 3.0% From Prior Quarter and an Increase of 11.1% From December 31, 2016 February 27th, 2018

Nanowire LED Innovator Aledia Announces 30 ($36M) Million Series-C Financing: Intel Capital Joins Existing Investors to Commercialize Certain Nanowire-LED Technologies for Mobile Displays January 29th, 2018

Nanomedicine

Remote control of transport through nanopores: New study outlines key factors affecting the transfer of molecules through biological channels May 24th, 2018

New blood test rapidly detects signs of pancreatic cancer May 17th, 2018

Elastic microspheres expand understanding of embryonic development and cancer cells May 15th, 2018

Nanomedicine -- Targeting cancer cells with sugars May 14th, 2018

Announcements

Switching with molecules: Molecular switch will facilitate the development of pioneering electro-optical devices May 25th, 2018

Tunable diamond string may hold key to quantum memory: A process similar to guitar tuning improves storage time of quantum memory May 24th, 2018

Remote control of transport through nanopores: New study outlines key factors affecting the transfer of molecules through biological channels May 24th, 2018

2018 Kavli Prizes in Astrophysics, Nanoscience, and Neuroscience to be Announced Live on May 31: Live announcement at the Norwegian Academy of Science and Letters to be streamed live at World Science Festival Event May 24th, 2018

Nanobiotechnology

Remote control of transport through nanopores: New study outlines key factors affecting the transfer of molecules through biological channels May 24th, 2018

New blood test rapidly detects signs of pancreatic cancer May 17th, 2018

Nanomedicine -- Targeting cancer cells with sugars May 14th, 2018

NanoBio Announces Corporate Name Change to BlueWillow Biologics and Closes $10M Series A Financing: Move Reflects Focus on Advancing Several Intranasal Vaccines to Human Studies May 9th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project